Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders. Its lead drug candidate, VK2809, is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis and NAFLD. The company also has other drug candidates in various stages of development for different conditions.

Viking Therapeutics, Inc.

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Viking Therapeutics, Inc. (Nasdaq:VKTX) is a clinical-stage company focused on the development of first-in-class or best-in-class therapies for metabolic and endocrine disorders. Our most advanced candidate is a non-steroidal selective androgen receptor modulator (SARM) currently in Phase 2 trial for the treatment recovery from hip fracture surgery. Our thyroid receptor beta (TRb) agonist platform, also in Phase 2, is being developed for lipid disorders such as hypercholesterolemia and fatty liver diseases such as non-alcoholic steatohepatitis (NASH) as well as for rare diseases of glycogen storage disease (GSD 1a) and X-linked adrenoleukodystrophy, or X-ALD. See more at http://www.vikingtherapeutics.com



COM:VIKINGTHERAPEUTICS

Viking Therapeutics, Inc.

Last Close

51.63

22/11 21:00

Market Cap

4.72B

Beta: -

Volume Today

2.63M

Avg: -

name

homepage url

country

linkedin url

crunchbase url

employee count

sector

industry

monthly webtraffic

monthly webtraffic growth

stage

raised capital

Description

peer of

competitor of

Metrics